Home › Compare › NWKLF vs ABBV
NWKLF yields 40.73% · ABBV yields 3.06%● Live data
📍 NWKLF pulled ahead of the other in Year 1
Combined, NWKLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NWKLF + ABBV for your $10,000?
Network International Holdings plc operates as a digital commerce enabler in the Middle East and Africa. The company provides technology-enabled payment solutions to merchants and financial institutions. It offers merchant solutions, which include payment solutions, such as N-Genius payment device, N-Genius mini payment device, and On-the-Go payment device; retail integrated and hospitality solutions; and N-Genius online, buy now pay later, and DPO pay online payment solutions. The company also provides value-added services, including SmartView interactive dashboards, SmartView performance report, dynamic currency conversion, multicurrency online, easy payment plan, 3D secure, and network self-services; and acquiring processing and smart bundle solutions. In addition, it offers card and processing solutions comprising debit and credit card, prepaid card, and commercial card solutions; fraud solutions; loyalty solutions; instant issuance, card control, 3D secure, SmartView, API, and payment plan services; and issuer services. Network International Holdings plc was founded in 1994 and is headquartered in Dubai, the United Arab Emirates.
Full NWKLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.